Medical Tech Stock Aethlon Medical's (NASDAQ: AEMD) Australian Oncology Clinical Trial Update and Progress Hemopurifier® shows Changes in Extracellular Vesicles, Extracellular MicroRNAs, and T Cell Numbers SAN DIEGO, October 7, 2025 – ( Investorideas.com Newswire) Breaking Medical Tech News- Aethlon Medical, Inc. (Nasdaq: AEMD) today provided observations on the preliminary changes in extracellular vesicle (EV), microRNA and lymphocyte counts in the first patient cohort in its ongoing oncology clinic ...

, /PRNewswire/ -- Aethlon Medical, Inc. ("Aethlon" or the "Company") (Nasdaq: AEMD) today provided observations on the preliminary changes in extracellular vesicle (EV), microRNA and lymphocyte counts in the first patient cohort in its ongoing oncology clinical trial in Australia. The study is a safety, feasibility, and dose- finding trial evaluating the company's Hemopurifier (HP) in patients with cancer not responding to anti-PD-1 therapy. "As we promised during our last earnings call, we are sharing ear ...

Key Takeaways Rigel's Tavalisse posted $68.5M in H1 2025 sales, which increased 44% year over year.Rezlidhia sales rose 31% to $13.1M, with Gavreto adding incremental revenues in 1H 2025.R289 phase Ib study in MDS moves to dose expansion, with dose escalation data expected later in 2025.Rigel Pharmaceuticals (RIGL) is making continued advancement related to the development of its hematology and oncology pipeline and products. The company’s first product, Tavalisse (fostamatinib disodium hexahydrate), has be ...

Genmab to Buy Cancer-Treatment Developer Merus For $8 Bln in Cash https://t.co/SOvnBOpIrE ...

Doctors are experimenting with using lower doses of blockbuster cancer drugs. It could help hundreds of thousands of lives — if pharmaceutical companies would allow it. https://t.co/p6z3ajkmUw ...

[Music] I thank the organizers for this beautiful wonderful program. Uh thank you so much uh director sir and his team. Um my father Shri Babradesh pan uh he was a freedom fighter.He lived more than 100 years and uh father had very beautiful connections. So I have utilized maximum uh with that I'm here with you all today. Connections are very very important in life.uh he was well connected with politicians and the business people all the social workers in Kaluri. Uh my mother Shrimati Ratama she sold the ve ...

Core Insights - Allarity Therapeutics, Inc. is a Phase 2 clinical-stage pharmaceutical company focused on developing stenoparib, a dual PARP and WNT pathway inhibitor, and its CEO has been invited to present at the Biomarkers & Precision Medicine 2025 conference in London [1][2] Company Overview - Allarity Therapeutics is dedicated to developing personalized cancer treatments, particularly stenoparib for advanced ovarian cancer patients, utilizing its Drug Response Predictor (DRP) technology [5] - The company has exclusive global rights for the development and commercialization of stenoparib, which was originally developed by Eisai Co. Ltd. [3] Drug Information - Stenoparib is an orally available, small-molecule dual-targeted inhibitor of PARP1/2 and tankyrase 1/2, showing potential therapeutic action against various cancers, including ovarian cancer [3] - The DRP companion diagnostic platform is designed to select patients likely to benefit from specific drugs based on gene expression signatures, enhancing therapeutic benefit rates [4] Conference Participation - CEO Thomas Jensen will present a talk titled "A Gene Expression Based Biomarker For Predicting Response To Treatment With Stenoparib" at the conference on October 1, 2025, and will be available for individual meetings to discuss business development opportunities [6][8]

Core Insights - The article highlights that small-cap biotech companies often attract attention for fundraising and partnerships, but occasionally the focus shifts to their scientific advancements [1] Company and Industry Summary - Small-cap biotech companies are frequently in the news for their fundraising efforts and strategic partnerships, which are critical for their growth and development [1] - The scientific progress made by these companies can sometimes take precedence over financial activities, indicating the importance of innovation in the biotech sector [1]

Core Insights - NovoCure's mission is to extend survival in aggressive cancer forms through Tumor Treating Fields technology [2] - The company is transitioning from a single indication focus, primarily on GBM, which generates $600 million in revenue, to a multi-indication platform [3] - By the end of 2026, NovoCure aims to have four products, creating a diversified revenue stream and a clear path to profitability [3]

New research suggests that encouraging the growth of healthy cells may prevent the spread of cancerous ones. We explain how that could be game-changing for treatments https://t.co/FQXBRX2QcA ...